FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
DMB Number:	3235-0287					
Estimated average burden						
ours per response						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person * Jeffrey B Davis				2. Issuer Name and Ticker or Trading Symbol ACCESS PHARMACEUTICALS INC [ACCP.OB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director _X_Officer (give title below) Other (specify below)					
(Last) (First) (Middle) C/O ACCESS PHARMACEUTICALS INC, 2600 STEMMONS FREEWAY SUITE 176				3. Date of Earliest Transaction (Month/Day/Year) 02/04/2009							Chie	f Executive	Officer		
(Street) DALLAS, TX 75207			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquir						red, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution D any (Month/Day	ate, if	Code (Instr. 8		4. Secur (A) or D (Instr. 3.	isposed	of (D)	red 5. Amount of Securities (D) Beneficially Owned Followi Reported Transaction(s) (Instr. 3 and 4)		Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	V	Amount	(A) or (D)	Price				(I) (Instr. 4)	
Common	Stock		02/04/2009			J <u>(1)</u>		5,950	A	\$ 3	173,250	73,250		I	By Lake End Capital LLC (2)
Common	Stock		02/04/2009			J <u>(1)</u>		24,897	A	\$ 2.75	173,250	173,250		I	By Lake End Capital LLC (2)
Common	Stock		02/04/2009			J <u>(1)</u>		74,709	A	\$ 0.958	173,250			I	By Lake End Capital LLC (2)
Reminder: indirectly.	Report on a	separate line f	for each class of secu	nrities benefic	cially o	owned di	_		o resp	ond to	the colle	ection of in	formation	S	EC 1474 (9-
													espond un ntrol numb		02)
				Derivative Se								l			
Security	Conversion	3. Transactio Date (Month/Day/	n 3A. Deemed Execution Da	4. Transa Code	action 8)	5. Numb	per 6. I and (Mo	Date Exerc Expirationth/Day/	cisable on Date	7. T Amo Und Seco	itle and ount of derlying urities tr. 3 and	Derivative Security	f 9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Ownershi Form of Derivativ Security: Direct (D or Indirect	O) ct
				Code	v	(A) (I		e :	Expirati Date	on Title	Amount or Number of Shares				

Reporting Owners

Donatin Omen Name (Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Jeffrey B Davis C/O ACCESS PHARMACEUTICALS INC 2600 STEMMONS FREEWAY SUITE 176 DALLAS, TX 75207	X		Chief Executive Officer				

Signatures

Jeffrey B. Davis	02/04/2009
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Common Stock Dividend paid by Company for Preferred Stock Ownership
- (2) Jeffrey B. Davis is the managing member of Lake End Capital LLC

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.